Past and Present of Imaging Modalities Used for Prostate Cancer Diagnosis: Androgen Receptor Targeted Imaging of Prostate Cancer as a Future Modality for Early, Rapid and Efficient Diagnosis

Author(s): Tooba Khaliq, Rashid Rasheed, Dan Cheng, Tao Kong, Le Wang, Saira Azhar, Nazish Jabeen, Yi Lu*, Ghulam Murtaza*

Journal Name: Current Medical Imaging
Formerly: Current Medical Imaging Reviews

Volume 14 , Issue 6 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Prostate cancer is the second most prevailing cancer among men worldwide. In the most cases, prostate cancer is slowly progressing, whereas, in some cases, it is a rapidly progressing disease leading to the significantly high mortality rate. Thus, there is still demand for prostate-specific imaging in order to provide image-guided early diagnosis and for the provision of patient-specific therapy.

Discussion: Besides discussing traditional diagnostic approaches, this review illustrates a perspective on prostate cancer imaging summarizing current imaging approaches with a special focus on Prostate Specific Membrane Antigen (PSMA), Bombesin (BN) and Androgen Receptor (AR) targeted imaging using Positron Emission Tomography (PET) and Single Positron Emission Computed Tomography (SPECT) based on 99mTc and other radiotracers. Here, the prostate biology is reconsidered for nuclear imaging as future modality for early, rapid and efficient diagnosis of prostate cancer.

Conclusion: Future direction in prostate cancer imaging involves the development of androgen receptor based imaging using nonsteroidal antiandrogen agent for early diagnosis of prostate cancer.

Keywords: Prostate cancer, prostate-specific membrane antigen, radiotracer, single photon emission computed tomography, positron-emission tomography, patient-specific therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 17 July, 2017
Page: [874 - 886]
Pages: 13
DOI: 10.2174/1573405613666170718093336
Price: $65

Article Metrics

PDF: 19